Trial Profile
A Pilot Study of Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Resectable or Potentially Resectable Pancreatic Adenocarcinoma (PDAC)
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 24 Jun 2021
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Jun 2021 Status changed from active, no longer recruiting to completed.
- 24 Jan 2019 Planned number of patients changed from 16 to 20.
- 24 Jan 2019 Planned End Date changed from 1 Sep 2018 to 9 Aug 2023.